Capital International Investors Increases Position in Cytokinetics, Incorporated $CYTK

Capital International Investors grew its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 0.9% during the third quarter, Holdings Channel reports. The firm owned 1,178,780 shares of the biopharmaceutical company’s stock after acquiring an additional 10,670 shares during the quarter. Capital International Investors’ holdings in Cytokinetics were worth $64,786,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lisanti Capital Growth LLC acquired a new stake in Cytokinetics during the 3rd quarter worth approximately $2,697,000. Sanders Morris Harris LLC acquired a new position in shares of Cytokinetics in the third quarter worth $1,182,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Cytokinetics in the third quarter worth $1,359,000. Moody Aldrich Partners LLC purchased a new stake in shares of Cytokinetics during the third quarter worth $4,532,000. Finally, Norges Bank acquired a new stake in shares of Cytokinetics in the second quarter valued at $39,122,000.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings/investor call framed a “high‑stakes” commercial launch as Cytokinetics shifts into commercialization — investors see successful market uptake as material revenue upside. Read More.
• Positive Sentiment: An insider exercised options valued at roughly $920k+ as the drug hit the market — often read as insiders monetizing launch value and signaling commercialization is underway. Read More.
• Positive Sentiment: Analyst activity remains constructive: several firms raised price targets and some maintain buy ratings, leaving a consensus target materially above current levels — supportive for medium‑term upside.
• Neutral Sentiment: Reported short‑interest data for early March shows “0” shares and a 0.0 days ratio — this is almost certainly a data/reporting anomaly rather than a real change in short positioning; treat as non‑informative until updated.
• Negative Sentiment: Insider sales on March 9: CEO Robert I. Blum sold 7,931 shares (~$481.6k) and EVPs Fady I. Malik and Andrew Callos sold 2,907 and 2,582 shares respectively at about $60.72 — substantial executives remain holders, but these disclosures look like near‑term profit‑taking and can weigh on sentiment. SEC filings: CEO Form 4 (Read More.), Malik Form 4 (Read More.), Callos Form 4 (Read More.).

Insiders Place Their Bets

In other Cytokinetics news, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the sale, the director owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Andrew Callos sold 2,582 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $60.72, for a total transaction of $156,779.04. Following the sale, the executive vice president owned 47,858 shares of the company’s stock, valued at $2,905,937.76. This represents a 5.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 96,113 shares of company stock worth $5,994,726 in the last three months. 2.70% of the stock is owned by company insiders.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $63.63 on Thursday. Cytokinetics, Incorporated has a 12 month low of $29.31 and a 12 month high of $70.98. The firm has a market capitalization of $7.84 billion, a PE ratio of -9.74 and a beta of 0.56. The business’s fifty day moving average price is $64.02 and its 200 day moving average price is $60.10.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. Cytokinetics’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned ($1.26) earnings per share. As a group, equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CYTK shares. Leerink Partners reiterated an “outperform” rating on shares of Cytokinetics in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Morgan Stanley set a $90.00 price target on Cytokinetics in a research report on Thursday, January 8th. Citizens Jmp lifted their price objective on Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a research note on Wednesday, February 25th. Finally, HC Wainwright boosted their price objective on Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.00.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.